©The Author(s) 2026.
World J Transplant. Mar 18, 2026; 16(1): 103656
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.103656
Published online Mar 18, 2026. doi: 10.5500/wjt.v16.i1.103656
Table 2 Univariable and multivariable logistic regression analysis of the predictors of post-transplant tertiary hyperparathyroidism
| Variables | Univariable analysis | Multivariable model | |||||
| n | OR | 95%CI | P value | OR | 95%CI | P value | |
| Age (per decade) | 887 | 1.17 | 1.03-1.33 | 0.016 | 1.36 | 1.15-1.62 | < 0.001 |
| Gender: Female | 887 | 1.10 | 0.75-1.62 | 0.62 | |||
| Ethnicity | 871 | 0.033 | - | - | - | ||
| White | 1 | - | - | - | - | ||
| Asian1 | 0.49 | 0.24-0.89 | 0.33 | 0.14- 0.70 | 0.006 | ||
| Black | 1.85 | 0.51-5.41 | 0.79 | 0.16-3.02 | 0.75 | ||
| Other | 0.00 | 0.00-0.00 | 0.00 | 0.00-0.00 | 0.98 | ||
| Pretransplant body mass index | 887 | 1.00 | 0.98-1.03 | 0.71 | - | - | - |
| Primary renal disease | 887 | 0.044 | - | - | - | ||
| Adult polycystic kidney disease | 1 | - | - | - | - | ||
| Glomerulonephritis | 1.34 | 0.68-2.81 | - | - | - | ||
| Diabetic kidney disease | 0.79 | 0.31-1.94 | - | - | - | ||
| Hypertensive kidney disease | 1.33 | 0.50-3.43 | - | - | - | ||
| Reflux/chronic pyelonephritis | 2.70 | 1.32-5.79 | - | - | - | ||
| Unknown | 1.40 | 0.67-3.06 | - | - | - | ||
| Other | 1.63 | 0.72-3.73 | - | - | - | ||
| Pre-emptive transplant | 887 | 0.50 | 0.31-0.78 | 0.002 | |||
| Pretransplant diabetes | 887 | 0.88 | 0.51-1.44 | 0.61 | - | - | - |
| Donor type: Living donor | 887 | 0.52 | 0.32-0.82 | 0.004 | - | - | - |
| Total human leukocyte antigen mismatch | 887 | 1.05 | 0.92-1.20 | 0.44 | - | - | - |
| Immunosuppression | 887 | 0.75 | - | - | - | ||
| Tacrolimus | 1 | - | - | - | - | ||
| Mammalian target of rapamycin inhibitor | 1.68 | 0.37-5.47 | - | - | - | ||
| Cyclosporin | 0.98 | 0.48-1.84 | - | - | - | ||
| Antimetabolite | 887 | 0.68 | - | - | - | ||
| None | - | - | - | - | - | ||
| Mycophenolic acid | 0.96 | 0.54-1.83 | - | - | - | ||
| Azathioprine | 0.74 | 0.33-1.68 | - | - | - | ||
| Corticosteroid regime | 887 | 0.023 | - | - | - | ||
| < 6 months of glucocorticoid | - | - | - | - | - | ||
| > 6 months glucocorticoid | 1.55 | 1.06-2.28 | - | - | - | ||
| Total ischaemia time | 887 | 1.03 | 1.00-1.05 | 0.038 | 1.03 | 1.00-1.07 | 0.048 |
| Dialysis vintage | 887 | 1.19 | 1.12-1.26 | < 0.001 | 1.12 | 1.04-1.20 | 0.002 |
| Baseline eGFR (per 10 mL/minute increase) | 887 | 0.98 | 0.90-1.05 | 0.66 | - | - | - |
| History of acute rejection | 838 | 1.62 | 0.93-2.72 | 0.086 | 2.37 | 1.19-4.60 | 0.012 |
| The eGFR slope | 887 | 0.93 | 0.89-0.97 | 0.001 | 0.91 | 0.87-0.96 | 0.001 |
| Median pretransplant calcium (per decile increase) | 887 | 1.35 | 1.25-1.46 | < 0.001 | 1.38 | 1.26-1.51 | < 0.001 |
| Median pretransplant phosphate (per decile increase) | 887 | 1.05 | 0.99-1.12 | 0.13 | - | - | - |
| Median pretransplant parathyroid hormone (per decile increase) | 887 | 1.26 | 1.17-1.36 | < 0.001 | 1.31 | 1.20-1.43 | < 0.001 |
| Posttransplant diabetes | 831 | 1.50 | 0.91-2.39 | 0.11 | - | - | - |
| Smoking history | 816 | 0.077 | 0.070 | ||||
| None-smoker | - | - | - | - | |||
| Current smoker | 0.53 | 0.24-1.02 | 0.48 | 0.20-1.02 | |||
- Citation: Hanson S, Menendez Lorenzo J, Chukwu CA, Rao A, Middleton R, Kalra PA. Incidence, risk factors and survival outcomes of post-transplant tertiary hyperparathyroidism in kidney recipients. World J Transplant 2026; 16(1): 103656
- URL: https://www.wjgnet.com/2220-3230/full/v16/i1/103656.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i1.103656